´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2020-07-24±³À°ÀÏÀÚ : 2020-07-24
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : ¿ì¿µ¼·
¿¬¶ôó : 02-3779-1139
À̸ÞÀÏ :
woo.youngsup@hotmail.com ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 160¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 3¸¸¿ø, ºñȸ¿ø 6¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦ ´çÀϵî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 8¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:30~09:50 Phenotype difference´Â ¾î¶°ÇÑ°¡? ±èÁö¼±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:50~10:10 Etiology¿¡ Â÷ÀÌ°¡ Àִ°¡? ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:10~10:40 µ¿¹ÝÀÌȯ°ú Àå±â ¿¹ÈÄÀÇ Â÷ÀÌ´Â? Á¤Á¾Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 09:30~09:50 Monoamine hypothesis: Facts, fiction, and controversy ³ª°æ¼¼(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 09:50~10:10 Biological differences among unipolar, bipolar, and mixed depression °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 10:10~10:40 Neurobiology of depression: An integrated view Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:15 ADHD°¡ µ¿¹ÝµÈ ±âºÐÀå¾Ö ±è½Â°ï(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:15~11:35 ADHD°¡ µ¿¹ÝµÈ ¾ËÄÚ¿ÃÀÇÁ¸ ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:35~12:05 ADHD°¡ µ¿¹ÝµÈ ºÒ¾ÈÀå¾Ö ¹× ƽÀå¾Ö ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 10:55~11:15 Identification and management of tachyphylaxis to antidepressant treatment °í¿µÈÆ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 11:15~11:35 Treatment using thyroid hormone in patients with mood disorder ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 11:35~12:05 Managing geriatric bipolar disorder: Use of lithium and anticonvulsants ÃßÀÏÇÑ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:05~12:35 AP polypharmacy; Pros and cons in the practice ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:35~13:05 Clinical benefit of ABILIFY MAINTENA¢ç on AP polypharmacy ¹èÄ¡¿î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 12:05~12:35 ADHD Ä¡·á¿¡¼ ´Üµ¶¿ä¹ýÀÇ Çö½Ç°ú Á¦ÇÑÁ¡ ½É¼¼ÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 12:35~13:05 ADHD Ä¡·á¿¡¼ º´ÇÕ¿ä¹ýÀÇ È¿°ú¿Í ¾ÈÀü¼º ¼Á¤¼®(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:20~13:50 The effective management of female MDD patients with Pristiq¢ç ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:50~14:20 Comprehensive consideration for elderly MDD patients with Pristiq¢ç ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 13:20~14:20 Evidence based and empirical based medicine in mood disorders: Pros and cons ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:20~14:40 Neurobiology of creativity ±è¾çÅÂ(°è¸íÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:00 Relationship between temperament and creativity ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:00~15:30 Effect of illness and medication on creativity ±è¿øÇü(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 14:20~14:40 BDNF and cytokine À̺ÐÈñ(¸¶À½°ú¸¶À½ Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 14:40~15:00 EEG and QEEG ÀÌÀç¿ø(ÀÌÁöºê·¹ÀÎ Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 15:00~15:30 GWAS and polygenic risk score ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:45~16:05 General principle Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:05~16:25 Psychodynamic and interpersonal features in bipolar patients ±¸º»ÈÆ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:25~16:55 Individual and group psychotherapy in bipolar patients Àå¼¼Çå(ºÀ»ýº´¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 15:45~16:05 Major depressive disorder ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 16:05~16:25 Bipolar disorder È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 07-24 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀÇ½Ç 16:25~16:55 DSM-5 ¹ßÇ¥ Ãʱâ¿Í ÇöÀç±îÁöÀÇ ÀÎ½Ä º¯È Àå½ÂÈ£(¿ø±¤ÀÇ´ë)